Background: Sofosbuvir (SOF)-based regimens have been associated with renal function worsening in HCV patients with estimated glomerular filtration rate (eGFR) ≤ 45 ml/min, but further investigations are lacking. Aim: To assess renal safety in a large cohort of DAA-treated HCV patients with any chronic kidney disease (CKD). Methods: All HCV patients treated with DAA in Lombardy (December 2014-November 2017) with available kidney function tests during and off-treatment were included. Results: Among 3264 patients [65% males, 67% cirrhotics, eGFR 88 (9-264) ml/min], CKD stage was 3 in 9.5% and 4/5 in 0.7%. 79% and 73% patients received SOF and RBV, respectively. During DAA, eGFR declined in CKD-1 (p < 0.0001) and CKD-2 (p = 0.0002) patients, with corresponding rates of CKD stage reduction of 25% and 8%. Conversely, eGFR improved in lower CKD stages (p < 0.0001 in CKD-3a, p = 0.0007 in CKD3b, p = 0.024 in CKD-4/5), with 33-45% rates of CKD improvement. Changes in eGFR and CKD distribution persisted at SVR. Baseline independent predictors of CKD worsening at EOT and SVR were age (p < 0.0001), higher baseline CKD stages (p < 0.0001) and AH (p = 0.010 and p < 0.0001, respectively). Conclusions: During DAA, eGFR significantly declined in patients with preserved renal function and improved in those with lower CKD stages, without reverting upon drug discontinuation.
Introduction
Worldwide, 71 million people are chronically infected with the hepatitis C virus (HCV) [1] . Direct-acting antivirals (DAA) provided high sustained virological response (SVR) rates in reallife cohorts [2] [3] [4] , without major safety signals [5] [6] [7] [8] [9] [10] [11] [12] [13] . Most of these studies have excluded patients with chronic kidney disease (CKD) as Sofosbuvir (SOF) is not recommended in patients with an estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m 2 [14, 15] . The few studies analyzing the safety of SOF on kidney function are relatively small, heterogeneous and include highly selected patients. Whilst some studies reported good safety and efficacy profiles of SOF-based regimens in HCV patients on dialysis [16] [17] [18] , one large study from the US reported an increased risk of adverse events among patients with moderate renal impairment (eGFR ≤45 ml/min/1.73 m 2 ) treated with SOF [19] . However, limiting these findings was the absence of complete clinical data as well as a univocal definition of worsening renal function, and no information was provided regarding patients with eGFR values >45 ml/min/1.73 m 2 . Unfortunately, this data has not been further investigated, due to the more recent availability of molecules without renal metabolism [20] [21] [22] [23] and with pangenotypic activity [24] , which have simplified the management of HCV patients with CKD [25, 26] . Nevertheless, due to the presence of protease inhibitors, they are contraindicated in decompensated patients and carry an increased risk of drug-drug interactions. Therefore, SOF-based regimens may still represent the best treatment option to achieve viral eradication in some of the patient population.
We therefore investigated the impact of different DAA regimens on renal safety in a large cohort of HCV patients, displaying different degrees of renal impairment.
Material and methods

Patients
This was a retrospective, multicenter study analyzing data from the NAVIGATORE-Lombardia web-based Platform, which is based on REDCap (Research Electronic Data Capture; http://projectredcap.org) and includes data from consecutive HCV patients treated with DAA in Lombardy, Italy. Antiviral therapy is usually prescribed at physician's discretion, according to drug label and international recommendations [2] [3] [4] .
Included were patients treated within the NAVIGATORELombardia Network between December 2014 and November 2017 with available complete renal function data at baseline, end of treatment (EOT) and 12 weeks after treatment. According to Italian Medicines Agency (AIFA, Associazione Italiana del Farmaco) reimbursement rules, exclusion criteria were Child-Pugh-Turcotte (CPT)-C score and active hepatocellular carcinoma (HCC), where DAA treatment was not allowed outside the liver transplant (LT) waiting-list (WL) [27] .
In Italy, patients belonging to the following categories could be treated with DAA: (1) CPT-A or CPT-B cirrhosis, (2) post-LT recurrence, (3) HCV extra-hepatic manifestations (EHM), (4) F3 fibrosis, (5) patients on LT WT, (6) post-bone marrow transplant (BMT) or solid organ transplant (SOT), (7) F2 fibrosis (treated with PegIFN before April 2017), (8) F0-F1 fibrosis, (9) health-workers; (10) CKD on dialysis, (11) patients on BMT or SOT WT.
Informed consent was obtained from each patient included in the study. The study protocol conforms to the Ethical Guidelines of the 1975 Declaration of Helsinki (6th revision) as reflected in a priori approval by the Institutions' Human Research Committees.
Measurements
Fibrosis stage was assessed clinically, histologically or noninvasively by transient elastography (TE). Liver stiffness measurement (LSM) cut-offs were: <7.0 kPa for F0-F1, 7.0-9.9 kPa for F2, 10.0-12.9 kPa for F3 (advanced fibrosis), ≥13.0 kPa for F4 (cirrhosis) [4, 28, 29] [25, 30] .
SVR was undetectable HCV-RNA 12 weeks after the EOT. Patients consented to make available their medical records for the study, whose protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.
Patients were assessed with complete blood examinations and HCV-RNA quantification at baseline and every 4 weeks while on treatment, at post-treatment weeks 4, 12, 24 and at 6-month intervals thereafter. Serum creatinine was assessed at baseline, EOT, and 12 weeks after treatment completion (SVR12).
Study endpoints
Primary endpoint was the impact of DAA regimens on renal safety, i.e. changes in eGFR values and/or CKD stages (one stage, at least). Secondary endpoints were (1) the impact of DAA regimens on renal function according to baseline CKD stage and (2) effectiveness of DAA therapies in the overall population and according to CKD stage.
Statistical analysis
Categorical variables were reported as frequencies (percentages) and continuous variables as median (range). Categorical variables were compared using the 2 
Results
Baseline features of the cohort
Among the 3264 patients included in the study, median age was 61 (21-88) years and most were males (65%), cirrhotics (67%), and HCV genotype 1 (Table 1) . CKD stage was 1 in 1552 (48%), 2 in 1377 (42%), 3a in 235 (7%), 3b in 77 (2%) and 4 in 22 (1%) patients; only one patient was on dialysis (CKD-5) (Fig. 1) . As expected, most baseline characteristics differed between patients receiving or not receiving SOF-based regimens (Table S1 ). Overall, 242 (7%) patients had undergone a transplant (LT in 92%, BMT in 2% and SOT in 6%). Baseline eGFR was lower in females (p < 0.0001), in the elderly (p < 0.0001) and in those with milder liver disease (p < 0.0001) and/or co-morbidities, such as arterial hypertension (p < 0.0001) and diabetes (p < 0.0001) (Table 1) . Moreover, eGFR values significantly differed between patients classified according to AIFA criteria (p < 0.0001 for all comparisons), with the lowest eGFR values observed in transplanted patients ( Figure S1 ). Details on prescribed DAA regimens are reported in Table S2 . Increased rates of premature RBV withdrawal were observed in patients with advanced CKD (p = 0.001) (Table S2 ).
Baseline renal parameters
Overall, baseline eGFR values (Table 2) (Table S3) . Similarly, no changes in eGFR values were observed at EOT or SVR time-points, when comparing data from patients receiving or not receiving SOFbased regimens (Table S3) .
In contrast, baseline eGFR was higher in patients treated with RBV, in the overall population [89 Table 2 ).
Renal function during and after DAA treatment
On-treatment period
In the overall population, eGFR decreased during treatment from 88 (9-264) ml/min/1.73 m 2 to 86 (11-325) ml/min/1.73 m 2 (p < 0.0001) ( Table 2) . However, when analysing data according to baseline renal function, eGFR declined only in patients with baseline eGFR ≥60 ml/min/1.73: in CKD-1 patients from 144 (90-264) to 140 (18-325) ml/min/1.73 m 2 (p = <0.0001) and in CKD-2 from 78 (60-89) to 77 (11-299) ml/min/1.73 m 2 (p = 0.0002), respectively. Thus, the most significant decline was observed in CKD-1 vs. CKD-2 patients (p = 0.002). On the contrary, in patients with eGFR <60 ml/min/1.73 m 2 renal function significantly improved from 51 (9-59) to 52 (12-189) ml/min/1.73 m 2 (p < 0.0001) ( Table 2 ). This was confirmed in the subgroup of patients treated with SOF-based regimens (CKD-3a p = 0.0016, CKD-3b p = 0.0028, CKD-4 p = 0.023).
Despite the significant decline in eGFR values in the overall cohort, the rate of CKD stage reduction was limited (16%), and most frequent in subjects with the highest baseline eGFR values (at baseline, CKD stage was 1 in 73%, 2 in 20%, 3a in 5% and 3b in 1%). Conversely, 359 (11%) patients improved their CKD stage from baseline to EOT (Table 3) . In this case, rates of CKD improvement were higher in patients with the lowest pre-treatment CKD stage. In fact, in the overall population, baseline renal function influenced changes in CKD stage at EOT (p < 0.0001). This effect was maintained in patients treated with SOF (p < 0.0001) and/or RBV (p = 0.0005), but not in those patients not taking SOF (p = 0.47) and/or not taking RBV (p = 0.06) (Table S5) .
At univariate analysis, age (p = 0.05), higher baseline CKD stage (p < 0.0001) and arterial hypertension (p = 0.007) were associated with CKD reduction at EOT (Table 4) . At multivariate analysis these factors were all independent predictors of CKD stage worsening (Table S5) .
Off-treatment period
Twelve weeks after treatment, no changes in eGFR values were observed with respect to EOT, in the overall population and according to baseline CKD stage (Table 2) . No patients renal function reverted to pre-treatment values (Table 2) .
Overall, 617 (19%) patients displayed any CKD reduction at SVR when compared to baseline (Table 3) ; however, most of them (53%) had already worsened during treatment. On the contrary, 367 (11%) patients showed an improvement in their CKD stage (Table 3) , with no significant changes when compared to EOT assessments, overall (Figs. 1, S2) and according to DAA regimen (Figs. 2A, B, S3A, S3B) .
Also in this case, changes in CKD stage were influenced by baseline eGFR values, in the overall population (p < 0.0001), and independently of the use of SOF (SOF vs. non-SOF: p < 0.0001 vs. p < 0.0043) and/or RBV (RBV vs. non-RBV: p < 0.0001 vs. p = 0.0001). Factors associated with CKD worsening at SVR were older age (p = 0.02), arterial hypertension (p = 0.0001), higher CKD stage at baseline (p < 0.0001) and EOT (p < 0.0001), and on-treatment CKD reduction (p < 0.0001) ( Table 4) . At multivariate analysis, age (p < 0.0001), baseline CKD stage (p < 0.0001) and arterial hypertension (p < 0.0001) were independent baseline predictors of CKD worsening at SVR (Table S5 ).
Effectiveness
Overall, 3134 (96%) patients achieved an SVR while 130 (4%) failed DAA-based therapy (126 relapses and 4 breakthroughs). SVR rates were similar independent of baseline eGFR (p = 0.47) (Table  S2) . Patients with treatment failure were most frequently males, HCV genotype 3, cirrhotics and treated with SOF-based and/or RBVcontaining regimens (Table S6) . 
Discussion
In a large cohort of HCV patients treated with different DAA regimens, we demonstrated that eGFR values significantly declined during antiviral treatment and did not revert after DAA withdrawal in patients with preserved baseline renal function. However, these changes were clinically significant in a limited subgroup of patients, who finally experienced changes in their CKD stages. In contrast, in patients with eGFR <60 ml/min/1.73 m 2 , renal function significantly improved, as well as in those patients treated with SOF-based regimens. To the best of our knowledge, this is the first study specifically investigating the impact of DAA on renal safety in the general population as well as in sub-groups of patients with suboptimal renal function.
In our cohort, most patients displayed baseline preserved renal function; the proportion of those with significant kidney impair- Table 2 eGFR modifications during and after treatment in the overall population and according to baseline renal function and DAA regimen (SOF and/or RBV use). ment was quite limited but in line with other real-life studies [9] [10] [11] [12] 19, 31] . The limited data so far published has been generated by studies designed to assess effectiveness and safety of DAA in real-life cohorts, without any specific reference to renal safety. Only Saxena et al. [19] reported a detrimental effect of former SOF-based therapies on renal function in 73 patients with eGFR ≤45 ml/min/1.73 m 2 from the TARGET cohort, which has not been confirmed in our study.
Although that study was specifically designed to evaluate safety (and efficacy) of SOF-based regimens in a large cohort of patients with varying baseline renal function, worsening renal function has not been unequivocally defined. In fact, both acute and chronic conditions, either potentially DAA-related or not, have been considered. Moreover, detailed clinical information regarding the overall cohort as well as patients with eGFR >45 ml/min/1.73 m 2 is lacking, and no comparisons with SOF-free regimens were possible.
Differing from what was described in the TARGET study, in our cohort we reported a beneficial DAA effect on renal function in patients with pre-treatment eGFR <60 ml/min/1.73 m 2 , including a hundred subjects with eGFR <45 ml/min/1.73 m 2 (23% CKD-4, 1% CKD-5). Among them, rates of CKD stage improvement were significant (33% CKD-3a, 40% CKD-3b, 45% CKD-4). We reported that changes in CKD stage were finally influenced by baseline renal function (i.e. CKD stage). Interestingly, renal function improvement was invariably observed in SOF-treated patients, and mostly occurred during therapy.
In line with our findings are results from the large real-life Spanish study by Calleja et al. reporting 50% and 61% rates of eGFR improvement in HCV patients with eGFR <60 ml/min/1.73 m 2 receiving SOF-free and SOF-based regimens, respectively [9] . Interestingly, they also observed a decline in eGFR values of 621 DAA-treated CKD-1 and CKD-2 patients. Supporting these results is data from Germany, where 450 patients treated with SOF-free (±RBV) regimens experienced a mean 3.8 (CKD-1) and 0.4 (CKD- Fig. 2 . CKD stages distribution at baseline, EOT and SVR time-points, according to SOF (2A) and RBV use (2B). CKD: chronic kidney disease; EOT: end of treatment; SVR: sustained virological response; eGFR: estimated glomerular filtration rate; SOF: Sofosbuvir; RBV: Ribavirin. * CKD-5 patients in SOF vs. non-SOF subgroups: SOF baseline n = 1, EOT n = 2, SVR n = 3; non-SOF baseline n = 0, EOT n = 1, SVR n = 2. * CKD-5 in RBV vs. non-RBV subgroups: RBV baseline n = 0, EOT n = 2, SVR n = 4; non-RBV baseline n = 1, EOT n = 1, SVR n = 1.
2) ml/min/1.73 m 2, eGFR decrease [11] . Findings from European studies are not unexpected, especially renal function worsening observed in patients with baseline preserved renal function, which usually exhausts in advanced CKD stages [32] .
In our study, overall SVR rates (96%) were comparable to those reported in registration trials [2, 3] and real-life studies [5, 6, [8] [9] [10] [11] [12] [13] , and were independent of baseline renal function, as previously reported [11, 12, 19, 33] . Interestingly, the highest SVR rates were achieved by those treated with SOF-free (p = 0.0003) and RBV-free (p = 0.0017) combinations. This is not unexpected, since the suboptimal combinations of SOF + RBV ± PegIFN or SOF + SMV ± RBV accounted for almost one third of all therapies containing SOF and RBV, and most patients had cirrhosis. Also in the TARGET cohort, patients treated with RBV-free regimens achieved the highest SVR rates [19] . Conversely, in more recent real-life studies, SVR rates were independent of the use of RBV [8, 9, 11] probably because former, sub-optimal SOF-based combinations were excluded.
Due to the large number of patients, as well as the availability of complete clinical data, our study also provided several meaningful but quite unexpected results.
Firstly, we found a lower than expected prevalence of cirrhosis among patients with moderate to severe CKD. This fact could reflect former AIFA eligibility criteria to DAA access [27] . Indeed, patients with end-stage liver disease, considered at increased risk of kidney failure, cannot be treated outside the LT waiting-list in Italy. On the other hand, during the first period after DAA approval, treatment was allowed only for a selected subgroup of patients with mild (F0-F2) liver disease, that mainly included conditions associated with an increased prevalence of CKD, such as EHM, or transplanted patients (LT, BMT, SOT) receiving immunosuppressants.
Our study also found that in clinical practice the use of SOF is not influenced by baseline renal function. Indeed, in our cohort baseline eGFR was similar in patients treated with or without SOF-based combinations, and most patients with eGFR <45 ml/min/1.73 m 2 (88% CKD-3 and 78% CKD-4/5) finally underwent SOF-containing regimens, against drug label and international recommendations [2] [3] [4] . Nevertheless, and as previously mentioned, also in these patients SOF use was associated with renal function improvement.
We acknowledge that our study suffers from some limitations. First, the overall number of patients with moderate to severe renal impairment included in our study remains limited, although in line with other large real-life studies. Therefore, no definitive conclusion can probably be drawn, as our findings on the independent role of SOF or RBV in patients with suboptimal renal function may require further validation. Moreover, in our study most patients received sub-optimal regimens, which are no longer endorsed by international recommendations. However, since data have been analysed according to SOF and/or RBV use, we have no reason to believe that inclusion of patients treated with more recent DAA combination would have affected study conclusions. Finally, whether changes in renal function observed during and shortly after DAA treatment could reverse during follow-up remains to be evaluated.
However, several strengths counterbalance these few limitations: this is the first study designed to specifically assess the impact of DAA on renal safety. To do that, for the first time we collected complete clinical data up to 12 weeks after treatment discontinuation. Finally, we analyzed data according to baseline CKD stage and DAA regimen (SOF and/or RBV use).
In conclusion, for the first time we have demonstrated that DAA treatment is associated with renal function impairment in patients with baseline preserved renal function tests, although clinically significant in a limited subgroup. On the contrary, and differently from what previously reported, an improvement in renal function was observed in patients with severe to moderate CKD, including those treated with SOF-based regimens. Particularly, this latter finding might support the use of SOF-containing regimens in a selected subgroup of patients, such as for example those with contraindications to protease inhibitors and concomitant kidney impairment. Finally, although in our cohort changes in renal function did not revert after treatment completion, further studies with longer follow-up would be needed to definitively assess the long-term renal outcome of patients treated with DAA.
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